Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Share News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Woodford Raises GBP500 Million From Flurry Of London Share Sales (ALLISS)

Mon, 10th Jun 2019 13:33

LONDON (Alliance News) - Over the past week, fund manager Neil Woodford's Woodford Investment Management has conducted a fire sale of its stakes in 20 London-listed companies - raising in excess of GBP500 million - after taking the decision to suspend withdrawals from his equity income fund.

Woodford Investment manages three funds: LF Woodford Income Focus Fund, LF Woodford Equity Income Fund and London-listed Woodford Patient Capital Trust.

LF Woodford Equity Income Fund on Monday last week said the suspension was due to "an increased level of redemptions", with the fund now needing time to "reposition" its portfolio invested in unquoted and less liquid stocks into more liquid investments.

Neil Woodford appeared in a video suggesting his firm faced having to hold a fire sale in order to meet the demand for redemptions from his flagship Woodford Equity Income Fund, which was reported to have hit GBP10 million a day. The stock market guru insisted that his firm, Woodford Investment Management, has a strategy in place to stabilise the fund so holders would eventually be able to access their investments.

According to stock market filings, since Monday last week, Woodford Investment Management has reduced its holdings in the following London listings, in order of the minimum approximate gross value of each disposal:

- vehicle marketplace BCA Marketplace PLC, to 7.14% from 12.59%, GBP78.7 million;

- subprime lender Provident Financial PLC, to 18.43% from 23.44%, GBP65.7 million;

- housebuilder Countryside Properties PLC, to 10.20% from 15.00%, GBP65.1 million;

- guarantor loan company Amigo Holdings PLC, to 5.57% from 10.03%, GBP57.3 million;

- housebuilder Crest Nicholson Holdings PLC, to 10.01% from 15.08%, GBP48.0 million;

- property investor NewRiver REIT PLC, to 14.9% from 22.3% across three days, GBP46.3 million;

- intellectual property commercialisation company IP Group PLC to 14.08% from 19.00%, GBP40.7 million;

- online estate agent Purplebricks Group PLC, to 19.25% from 28.88% across three days, GBP31 million;

- retailer Card Factory PLC to below 5% from 8.94%, GBP26.1 million; at the end of May, this stake already had been lowered from 10.06%;

- construction firm Watkin Jones PLC, to below 5% from 9.19%, GBP22.2 million;

- construction materials firm Breedon Group PLC to below 5% from 6.83%, GBP21.4 million;

- media firm Time Out Group PLC to below 5% from 16.06%, GBP13.2 million;

- outsourcer and construction firm Kier Group PLC, to 15.87% from 20.01%, GBP10.3 million;

- intellectual property commercialisation company Allied Minds, to 23.22% from 28.21%, GBP9.4 million;

- ten-pin bowling site operator Ten Entertainment Group PLC to 5.54% from 10.08%, GBP6.5 million;

- housebuilder Barratt Developments PLC, to below 5% from 5.07%, GBP4.0 million;

- housebuilder Taylor Wimpey PLC, to below 5% from 5.07%, GBP3.9 million;

- respiratory disease-focused pharma firm Circassia Pharmaceuticals PLC to 24.47% from 28.03%, GBP2.5 million;

- housebuilder Redrow PLC, to below 5% from 5.07%, GBP1.4 million;

- defence firm Babcock International PLC, to below 5% from 5.03%, GBP721,809; and

- drug discovery company e-Therapeutics PLC to 14.11% from 17.89%, GBP193,196.

In total, these sales will have raised proceeds of around GBP550 million for Woodford Investment Management.

More News
20 Mar 2018 16:14

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 21 March KingfisherFull Year ResultsAlpha FXFull Year In SportFull 22

Read more
9 Jan 2017 08:49

E-Therapeutics Hires Amgen Director As New Chief Executive

Read more
6 Oct 2016 11:23

DIRECTOR DEALINGS: e-Therapeutics Non-Executive Acquires Shares

Read more
14 Sep 2016 11:23

e-Therapeutics Development Director Steve Self To Step Down

Read more
13 Jul 2016 09:13

E-Therapeutics Chairman Takes On Executive Duties As CEO Steps Down

Read more
1 Jun 2016 08:03

e-Therapeutics Offer For Searchbolt Now Wholly Unconditional

Read more
25 May 2016 08:18

e-Therapeutics Focused On Validation Of Drug Discovery Platform

Read more
18 May 2016 15:05

AGM, EGM Calendar - Week Ahead

Read more
12 May 2016 11:13

DIRECTOR DEALINGS: E-Therapeutics Non-Executive Acquires Shares

Read more
11 May 2016 09:06

e-Therapeutics To Buy Searchbolt For GBP2.3 Million (ALLISS)

Read more
22 Mar 2016 11:40

E-Therapeutics Loss Widens As Active Projects Increase

Read more
15 Mar 2016 16:15

Earnings, Trading Statements Calendar - Week Ahead

Read more
15 Feb 2016 10:43

WINNERS & LOSERS SUMMARY: Reckitt Benckiser Results Please Investors

Read more
15 Feb 2016 09:45

E-Therapeutics depression drug trials miss targets

(ShareCast News) - Drug trials results for e-Therapeutics' depression treatment were not as successful as had been hoped, sending shares in the company sharply lower. Phase IIb clinical trials of the company's ETS6103 product did not achieve the aim of matching the efficacy of existing tricyclic ant

Read more
15 Feb 2016 08:20

E-Therapeutics Shares Drop As ETS6103 Trials Miss Primary Endpoint

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.